Skip to main content

Table 1 Patient characteristics

From: HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial

ID Age Primary tumor Recurrence
  Diagnosis Recurrence Inclusion Type FIGO stage Treatment Chemotherapy Region Interval prim-rec (months) Treatment Chemotype Interval Chemo-1st Vac (months)
1 40 41 41 cervix IB1 RH/CHRT Cisplatin LR 14    12.0
2 49 51 51 cervix IIB CHRT Cisplatin D 26    33.3
3 43 46 46 cervix IB1 RH/RT   D 37    
4 34 35 36 cervix IB2 CHRT/RH Cisplatin D 18    17.1
5 30 30 30 cervix IB1 RH/CHRT Cisplatin LR 6    5.3
6 55 56 56 cervix IIIB CHRT UK D 3    3.9
7 51 52 53 vagina IVB CHRT Carboplatin/Taxol D 16 RT   19.6
8 34 36 36 cervix IB1 RH/RT   D 19 CH Cisplatin/Topotecan 1.8
9 54 56 56 vagina IIB CHRT Cisplatin D 20 RT + HT   22.9
10 38 45 46 anus   CHRT UK LR 79 CHRT UK 41.9
11 44 46 46 cervix IIIB CHRT Cisplatin D 6    4.9
12 36 40 41 cervix IIA RH/CHRT Cisplatin D 40 HT + CH Carboplatin/Taxol 4.4
13 62 63 63 cervix IV RH/CHRT Cisplatin D 11    7.9
14 32 32 32 cervix IIB CHRT Cisplatin D 8    7.5
15 35 36 36 cervix IB1 SN/CHRT Cisplatin LR 4 SUR   4.3
16 54 54 54 cervix IV        
17 48 49 50 cervix IIB SUR   D 9    
18 58 59 59 cervix IB2 CHRT/RH Cisplatin D 11 RT   
19 52 54 54 cervix IIA CHRT Carboplatin/Cisplatin LR 31    37.4
20 39 40 41 cervix IB1 RH   D 14 CHRT + CH Carboplatin/Taxol 2.2
21 46 47 47 anus   CH Cisplatin/Vinorelbine   4    6.5
  1. LR, locoregional; D, distant metastasis; RH, radical hysterectomy; CH, chemotherapy; CHRT, chemoradiation; RT, radiotherapy; SN, Sentinal Node Procedure; HT, hyperthermia; SUR, surgery; UK, unknown; FIGO, International Federation of Gynecologists and Obstetricians. FIGO stage IB1 (clinical lesion ≤ 4 cm) and IB2 (clinical lesion > 4 cm) confined to the cervix. Stage II: tumor extension beyond the cervix, but not the distal 1/3 part of the vagina or the pelvic wall (stage IIA: involvement of the proximal 2/3 part of the vagina, stage IIB: parametrial involvement). Stage IIIB, carcinoma has extended to the pelvic wall and/or the distal 1/3 part of the vagina, and/or causes hydronefrosis. Stage IV, carcinomas spread to the mucosa of the bladder or rectum (stage IV A) or distant organs (stage IVB). The interval between the primary tumor and recurrence (prim-rec) is given in months. The interval between the chemotherapy and the 1st vaccination (Chemo-1st Vac) was calculated by using the starting date of the last given chemotherapy and the date of first vaccination as reference points.